Novartis Closes $12B Avidity Acquisition
BASEL, Switzerland – February 27, 2026 Novartis AG has successfully completed its acquisition of Avidity Biosciences, Inc., strengthening its...
biopharma acquisition
Advertisement
Mabwell’s 9MW3011 Achieves Positive Phase III Results in Moderate-to-Severe Plaque Psoriasis
SHANGHAI, CHINA – November 11, 2025 — Mabwell (688062.SH), an innovative biopharmaceutical company specializing in biologics for major diseases,...
Novartis Expands RNA Therapeutics Portfolio with Avidity Acquisition
Basel, Switzerland – October 26, 2025: Novartis AG announced its agreement to acquire Avidity Biosciences, a U.S. biotechnology company...
BioCryst Acquires Astria Therapeutics to Expand HAE Pipeline
BOSTON – October 14, 2025 – BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and Astria Therapeutics, Inc. (NASDAQ: ATXS) announced a...
Pfizer Expands Obesity Pipeline with $4.9B Metsera Acquisition
NEW YORK, September 22, 2025 – In a landmark move shaping the future of obesity and cardiometabolic disease treatments,...
Advertisement
